- Home
- QBTS vs IPHA Comparison
QBTS vs IPHA Comparison
Compare QBTS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QBTS | IPHA |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | QBTS | IPHA |
|---|---|---|
| Price | $25.34 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $30.08 | $5.00 |
| AVG Volume (30 Days) | ★ 31.6M | 21.7K |
| Earning Date | 11-06-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,144,000.00 | $14,839,695.00 |
| Revenue This Year | $194.34 | $22.29 |
| Revenue Next Year | $56.23 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 156.20 | N/A |
| 52 Week Low | $3.71 | $1.47 |
| 52 Week High | $46.75 | $3.51 |
Technical Indicators
Market Signals| Indicator | QBTS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 44.09 |
| Support Level | $23.57 | $1.80 |
| Resistance Level | $29.15 | $1.91 |
| Average True Range (ATR) | 2.20 | 0.07 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 52.45 | 14.24 |
Price Performance
Historical ComparisonAbout QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.